Literature DB >> 9283930

Costs of dementia and dementia care: a review.

A Wimo1, G Ljunggren, B Winblad.   

Abstract

Costs of dementia care constitute a great part of the total costs of care for elderly. Because the prevalence of dementia is linked to increasing age, and the number of the oldest old is rising, the costs of dementia care will increase considerably in the forthcoming decades. In this review, research describing costs of dementia care has been analysed and classified. The available database in this field is small, though expanding, and the methodological problems are obvious. Differences between countries, and between different periods of time, are difficult to analyse due to different methods of financing and organizing care. The main result of the present study is that the costs of dementia care differ considerably in the literature. One important reason for this variability is that the number of included cost categories vary, leading to a wide range of costs. Unpaid informal care forms a major part of the total costs, but the theory of costing informal care is complicated.

Entities:  

Mesh:

Year:  1997        PMID: 9283930

Source DB:  PubMed          Journal:  Int J Geriatr Psychiatry        ISSN: 0885-6230            Impact factor:   3.485


  20 in total

1.  Costs of Mini Mental State Examination-related cognitive impairment.

Authors:  L Jönsson; P Lindgren; A Wimo; B Jönsson; B Winblad
Journal:  Pharmacoeconomics       Date:  1999-10       Impact factor: 4.981

2.  Differences in resource use and costs of dementia care between European countries: baseline data from the ICTUS study.

Authors:  A Gustavsson; L Jonsson; T Rapp; E Reynish; P J Ousset; S Andrieu; C Cantet; B Winblad; B Vellas; A Wimo
Journal:  J Nutr Health Aging       Date:  2010-10       Impact factor: 4.075

3.  Assessing the health and economic impact of galantamine treatment in patients with Alzheimer's disease in the health care systems of different countries.

Authors:  Jaime Caro; Maribel Salas; Alexandra Ward; Denis Getsios; Kristen Migliaccio-Walle; Frances Garfield
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

4.  Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance.

Authors:  Michael Ewers; Cathal Walsh; John Q Trojanowski; Leslie M Shaw; Ronald C Petersen; Clifford R Jack; Howard H Feldman; Arun L W Bokde; Gene E Alexander; Philip Scheltens; Bruno Vellas; Bruno Dubois; Michael Weiner; Harald Hampel
Journal:  Neurobiol Aging       Date:  2010-12-14       Impact factor: 4.673

5.  The National Institute for Health and Clinical Excellence (NICE) and drug treatment for Alzheimer's disease.

Authors:  Steve Iliffe
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 6.  Assessment, measures and approaches to easing caregiver burden in Alzheimer's disease.

Authors:  Karl Farcnik; Michelle S Persyko
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

7.  Consensus statement on dementia education and training in Europe.

Authors:  M Tsolaki; V Papaliagkas; G Anogianakis; R Bernabei; M Emre; L Frolich; P J Visser; J P Michel; T Pirttila; M Olde Rikkert; H Soininen; T Sobow; B Vellas; F Verhey; B Winblad
Journal:  J Nutr Health Aging       Date:  2010-02       Impact factor: 4.075

8.  Assessment of Health Economics in Alzheimer's Disease (AHEAD): treatment with galantamine in Sweden.

Authors:  Frances B Garfield; Denis Getsios; J Jaime Caro; Anders Wimo; Bengt Winblad
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

9.  Potential cost-effectiveness of a family-based program in mild Alzheimer's disease patients.

Authors:  Janne Martikainen; Hannu Valtonen; Tuula Pirttilä
Journal:  Eur J Health Econ       Date:  2004-06

Review 10.  Economic considerations in the management of Alzheimer's disease.

Authors:  Carolyn W Zhu; Mary Sano
Journal:  Clin Interv Aging       Date:  2006       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.